Mental Health Consequences of COVID19 Infection in the French RMD Cohort

University Hospital, Lille296 enrolled

Overview

this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.

Study Type

OBSERVATIONAL

Enrollment

296

Conditions

Covid19 Systemic Autoimmune Disease Inflammatory Rheumatism Auto Inflammatory Diseases

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patient case: * Patient with inflammatory rheumatism, systemic autoimmune or autoimmune disease * With confirmed COVID-19 infection (at least one month prior to study inclusion) * Study information given to the patient * Patient affiliated to social security Patient control: * Patient with inflammatory rheumatism, systemic autoimmune disease or autoimmune disease. * Not having had a confirmed COVID-19 infection * Study information given to the patient * Patient affiliated to social security Exclusion Criteria: * Opposition to participation in the study by the patient and/or his legal representative * Adult patient not able to understand the implications and rules of the study * Protected adults under guardianship or curatorship

Outcomes

Primary Outcomes

Frequency of PTSD depending on whether or not autoimmune patients have experienced COVID

Time frame: at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection

Secondary Outcomes

Severity of PTSD depending on whether or not autoimmune patients have experienced COVID